Immutep, a clinical-stage biotech company developing immunotherapies for cancer and autoimmune disease, has announced encouraging new clinical data in first-line non-small cell lung cancer from INSIGHT-003.
Media Release Immuno-oncology combination of eftilagimod alpha and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II TACTI-002. | May 17, 2023
Immutep (IMMP) Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care. | March 31, 2023